Fig. 5From: Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysisComparing with initial value, there was a reduction in TRAbs at 6 (a) and 12 (b) month after RTX treatment for TAOBack to article page